Recent News

• 11.04.2025 - Amgen Q3 2025 Earnings Conference Call
• 11.04.2025 - Amgen Q3 2025 Earnings Conference Call
• 10.02.2025 - LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
• 10.02.2025 - LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
• 09.26.2025 - AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
• 09.26.2025 - AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
• 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.09.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.09.2025 - AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
• 09.09.2025 - AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Recent Filings

• 09.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors